Announcements Trials
Browse Landscape

Phase

Phase 3 6Phase 2 6Phase NA 5Phase 1/2 3Phase 2/3 1

Status

Unknown 2Recruiting 2Completed 1Active not recruiting 1

Sponsor Class

OTHER 4INDUSTRY 2

Study Type

Interventional 6

Sponsor

Cancer Type

Head & Neck 6Endocrine 6

Conditions

Breast Neoplasms 2760Carcinoma, Non-Small-Cell Lung 2260Prostatic Neoplasms 1425Colorectal Neoplasms 1290Neoplasms 1258Multiple Myeloma 1084Lung Neoplasms 1048Neoplasm Metastasis 994Leukemia, Myeloid, Acute 984Lymphoma 900Melanoma 862Pancreatic Neoplasms 818Ovarian Neoplasms 805Carcinoma, Hepatocellular 782Stomach Neoplasms 753Recurrence 750Leukemia 733Lymphoma, Non-Hodgkin 684Leukemia, Lymphocytic, Chronic, B-Cell 665Lymphoma, Large B-Cell, Diffuse 616Squamous Cell Carcinoma of Head and Neck 615Precursor Cell Lymphoblastic Leukemia-Lymphoma 605Head and Neck Neoplasms 596Brain Neoplasms 592Carcinoma, Renal Cell 586Glioblastoma 572Rectal Neoplasms 563Myelodysplastic Syndromes 522Sarcoma 521Lymphoma, Follicular 516

Interventions

surufatinib 1pembrolizumab 1lenvatinib 1donafenib 1Thyrotropin Alfa 1Sorafenib 1Injections 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 2 × Interventional × Differentiated Thyroid Cancer × Clear all
NCT05852223 2026-04-20

NePenThe

Istituti Clinici Scientifici Maugeri SpA

Phase 2 Recruiting
25 enrolled
EndocrineHead & Neck

Differentiated Thyroid Cancer

NCT04321954 2026-02-27

Lenvatinib in Locally Advanced Invasive Thyroid Cancer

Massachusetts Eye and Ear Infirmary

Phase 2 Active not recruiting
30 enrolled
EndocrineHead & Neck

Differentiated Thyroid Cancer

NCT04447183 2023-10-23

DTC

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Phase 2 Unknown
120 enrolled
EndocrineHead & Neck

Differentiated Thyroid Cancer

NCT05989425 2023-08-14

Surufatinib as Neoadjuvant Treatment for Locally Advanced or Metastatic Differentiated Thyroid Cancer

Fudan University

Phase 2 Recruiting
32 enrolled
EndocrineHead & Neck

Differentiated Thyroid Cancer

NCT01263951 2021-10-26

Study of Everolimus and Sorafenib in Patients With Advanced Thyroid Cancer Who Progressed on Sorafenib Alone

Thomas Jefferson University

Phase 2 Unknown
35 enrolled
EndocrineHead & Neck

Differentiated Thyroid Cancer

NCT02870569 2019-03-01

Phase 2 Trial of Donafenib in 131I-Refractory Differentiated Thyroid Cancer

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Phase 2 Completed
48 enrolled
EndocrineHead & Neck

Differentiated Thyroid Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡